BRK-B vs MSCI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
MSCI presents a compelling growth-at-a-quality story, trading at a premium valuation justified by best-in-class profitability and consistent earnings outperformance. Despite near-term price weakness (-5.3% over 1Y), the stock has delivered strong 5Y returns (+49.6%) on the back of durable double-digit earnings growth (19% YoY) and industry-leading margins. The company significantly outperforms its financial services peers in profitability and growth, with an operating margin of 56.43% and revenue growth of 9.5%, versus sector averages of 24.91% and 21.31% respectively. Analysts are aligned with a 'buy' consensus and a $655.06 target price, implying 15.9% upside, while insider selling remains a minor counterpoint.
Compare Another Pair
Related Comparisons
BRK-B vs MSCI: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and MSCI Inc. (MSCI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.